CGTX: Cognition Therapeutics, Inc. Total Debt to Capital

Cognition Therapeutics (CGTX) is actively developing drugs to combat dementia and retinal pathologies, making the market price shown on this chart a critical monitoring indicator. The business relies on protecting neural connections from harmful proteins to treat Alzheimer's disease. However, stability is hindered by a lack of profitability, dependence on external financing, and the risks of clinical trial failures, while the indicator stands at 0.02.

Evaluating the financial stability of Cognition Therapeutics (CGTX), I am analyzing the balance between borrowed funds and equity assets. This ratio measures the proportion of liabilities within the capital structure, determining the risk of bankruptcy or dependence on creditors. By analyzing the dynamics of the asset leverage level, an investor can discern the degree of the business's financial autonomy. For a biotechnological ecosystem focused on orphan therapy, low debt is critical, as it ensures the stable development of the diplabulin platform without the pressure of external obligations.